作者
Gunter Schumann, Elisabeth B Binder, Arne Holte, E Ronald de Kloet, Ketil J Oedegaard, Trevor W Robbins, Tom R Walker-Tilley, Istvan Bitter, Verity J Brown, Jan Buitelaar, Roberto Ciccocioppo, Roshan Cools, Carles Escera, Wolfgang Fleischhacker, Herta Flor, Chris D Frith, Andreas Heinz, Erik Johnsen, Clemens Kirschbaum, Torkel Klingberg, Klaus-Peter Lesch, Shon Lewis, Wolfgang Maier, Karl Mann, Jean-Luc Martinot, Andreas Meyer-Lindenberg, Christian P Müller, Walter E Müller, David J Nutt, Antonio Persico, Giulio Perugi, Mathias Pessiglione, Ulrich W Preuss, Jonathan P Roiser, Paolo M Rossini, Janusz K Rybakowski, Carmen Sandi, Klaas E Stephan, Juan Undurraga, Eduard Vieta, Nic van der Wee, Til Wykes, Josep Maria Haro, Hans Ulrich Wittchen
发表日期
2014/1/1
来源
European Neuropsychopharmacology
卷号
24
期号
1
页码范围
5-50
出版商
Elsevier
简介
There is recognition that biomedical research into the causes of mental disorders and their treatment needs to adopt new approaches to research. Novel biomedical techniques have advanced our understanding of how the brain develops and is shaped by behaviour and environment. This has led to the advent of stratified medicine, which translates advances in basic research by targeting aetiological mechanisms underlying mental disorder. The resulting increase in diagnostic precision and targeted treatments may provide a window of opportunity to address the large public health burden, and individual suffering associated with mental disorders.
While mental health and mental disorders have significant representation in the “health, demographic change and wellbeing” challenge identified in Horizon 2020, the framework programme for research and innovation of the European Commission (2014–2020), and in …
学术搜索中的文章
G Schumann, EB Binder, A Holte, ER de Kloet… - European Neuropsychopharmacology, 2014